secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001683168-25-003838
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows
---------------------------------------------------------------

- Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
- Net loss improved to $1.18M from $1.28M in prior-year quarter.
- Appointed Michel Roy as new Chief Commercial Officer.
- Launched 6 new generic drugs: two antibiotics, two GI drugs, two schizophrenia drugs.
- Completed preclinical studies confirming K1.1 mRNA-LNP activity against hepatocellular carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/0001683168-25-003838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-003838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer